Telix Pharmaceuticals (TLX) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TLX Community Fair Values
Create NarrativeSee what 115 others think this stock is worth. Follow their fair value or set your own to get alerts.
Telix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$24.78 |
| 52 Week High | AU$31.97 |
| 52 Week Low | AU$16.63 |
| Beta | 2.41 |
| 1 Month Change | -1.43% |
| 3 Month Change | -9.03% |
| 1 Year Change | 49.19% |
| 3 Year Change | 510.34% |
| 5 Year Change | 1,835.94% |
| Change since IPO | 3,118.18% |
Recent News & Updates
Shareholder Returns
| TLX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -3.1% | -1.4% | 0.4% |
| 1Y | 49.2% | -14.3% | 9.0% |
Return vs Industry: TLX exceeded the Australian Biotechs industry which returned -14.3% over the past year.
Return vs Market: TLX exceeded the Australian Market which returned 9% over the past year.
Price Volatility
| TLX volatility | |
|---|---|
| TLX Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.8% |
Stable Share Price: TLX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: TLX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 423 | Chris Behrenbruch | telixpharma.com |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
Telix Pharmaceuticals Limited Fundamentals Summary
| TLX fundamental statistics | |
|---|---|
| Market cap | AU$8.38b |
| Earnings (TTM) | AU$49.92m |
| Revenue (TTM) | AU$783.21m |
Is TLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLX income statement (TTM) | |
|---|---|
| Revenue | AU$783.21m |
| Cost of Revenue | AU$299.26m |
| Gross Profit | AU$483.95m |
| Other Expenses | AU$434.03m |
| Earnings | AU$49.92m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 61.79% |
| Net Profit Margin | 6.37% |
| Debt/Equity Ratio | 100.5% |
How did TLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/14 20:54 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Telix Pharmaceuticals Limited is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |
| Andrew Paine | CLSA |